The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers

J. Blake,G.R. Kolakowski,B. Tuch,K. Ebata,B. Brandhuber,S. Winski, K. Bouhana, N. Nanda,W.I. Wu,A. Parker, R. Hamor, P.D. Larsen,Francis J. Sullivan,W. DeWolf, N. Neitzel, L. Wollenberg,S. Andrews,S.M. Rothenberg

EUROPEAN JOURNAL OF CANCER(2016)

引用 6|浏览32
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要